Related Experiment Video
Updated: Jun 22, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin: safety in cardiac patients
Heart (British Cardiac Society)
|July 1, 2009
Summary
Metformin, an insulin sensitizer, rarely causes lactic acidosis, even with contrast procedures or in heart failure patients. Current guidelines for stopping metformin are not evidence-based and may be counterintuitive.
Area of Science:
- Pharmacology
- Clinical Medicine
- Nephrology
Background:
- Metformin is a widely used biguanide medication for managing type 2 diabetes by reducing blood glucose levels.
- Concerns exist regarding metformin-associated lactic acidosis (MALA), particularly in patients undergoing procedures with iodinated contrast media or those with renal impairment or heart failure.
Purpose of the Study:
- To review the evidence base for concerns surrounding metformin use in patients with specific risk factors for lactic acidosis.
- To evaluate the clinical implications of current guidelines recommending metformin cessation before contrast procedures.
Main Methods:
- Review of existing data and literature concerning metformin, lactic acidosis, iodinated contrast media, renal impairment, and heart failure.
- Analysis of the evidence supporting or refuting the risk of MALA in these clinical scenarios.
Main Results:
- Metformin treatment is infrequently the primary cause of lactic acidosis.
- A universal policy of stopping metformin 48 hours before and after procedures requiring iodinated contrast is not supported by evidence and contradicts best practices.
- In heart failure patients, metformin use is associated with improved outcomes, not increased risk of lactic acidosis.
Conclusions:
- The risk of metformin-induced lactic acidosis is low, even in patients with risk factors like renal impairment or heart failure.
- Current guidelines for routine metformin cessation around contrast procedures lack evidence and may be inappropriate.
- Metformin can be safely used in patients with heart failure, potentially offering therapeutic benefits.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...